Oramed Pharmaceuticals (ORMP) Set to Release Quarterly Earnings on Thursday

Oramed Pharmaceuticals (NASDAQ:ORMP) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to post earnings of $0.43 per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.

Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.52).

Oramed Pharmaceuticals Price Performance

Shares of ORMP stock opened at $4.00 on Tuesday. The firm has a market cap of $166.40 million, a PE ratio of 0.97 and a beta of 1.31. The company has a 50-day moving average of $4.44 and a two-hundred day moving average of $4.04. Oramed Pharmaceuticals has a 1-year low of $2.19 and a 1-year high of $5.47.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Wall Street Zen cut shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating. According to data from MarketBeat, Oramed Pharmaceuticals presently has an average rating of “Buy”.

Insider Buying and Selling

In related news, COO Joshua Hexter sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the sale, the chief operating officer directly owned 1,328,130 shares in the company, valued at approximately $5,989,866.30. The trade was a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $90,200.00. Following the sale, the chief financial officer owned 861,076 shares of the company’s stock, valued at approximately $3,883,452.76. The trade was a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is currently owned by insiders.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.